Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion type Assertion NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_head.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion description "[The anti-VEGF monoclonal antibody bevacizumab was approved in 2004 as a first-line treatment for metastatic colorectal cancer (CRC) in combination with chemotherapy and provided proof of principle for antiangiogenic therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_provenance.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion evidence source_evidence_literature NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_provenance.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion SIO_000772 23579861 NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_provenance.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion wasDerivedFrom befree-2016 NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_provenance.
- NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_assertion wasGeneratedBy ECO_0000203 NP1068613.RABtwMac7ZcNXlJOeAecSM-qk1hAIQYW4iSHTjQGHgvA8130_provenance.